These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35145817)

  • 1. Diagnosis and Management of Denosumab-Induced Hypocalcemia and Hypophosphatemia in the Setting of Metastatic Prostate Cancer.
    Flood MG; Rowley MA; Basnet A
    Cureus; 2022 Jan; 14(1):e20928. PubMed ID: 35145817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer.
    Muqeet Adnan M; Bhutta U; Iqbal T; AbdulMujeeb S; Haragsim L; Amer S
    Case Rep Nephrol; 2014; 2014():565393. PubMed ID: 25054070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
    Patell K; Ajay K; Al Armashi AR; Bawwab A; Ravakhah K
    J Oncol Pharm Pract; 2022 Apr; 28(3):698-702. PubMed ID: 34693819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
    Daga N; Joseph F
    BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SEVERE, PROLONGED, DENOSUMAB-INDUCED HYPOCALCEMIA WITH RECOVERY AFTER 111 DAYS OF HIGH-DOSE CALCIUM SUPPLEMENTATION.
    McCaleb RV; Johnson JT
    AACE Clin Case Rep; 2019; 5(1):e82-e85. PubMed ID: 31967007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
    Watkins KR; Rogers JE; Atkinson B
    Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Calcium Culprit: A Case of Denosumab-induced Hypocalcemia.
    Kalayanamitra R; Yaghnam I; Patel R; Groff A; Jain R
    Cureus; 2019 May; 11(5):e4768. PubMed ID: 31363449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
    Uhm SJ; Hall JA; Herrington JD
    J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer.
    Gunawan F; George E; Kotowicz M
    Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab-Induced Hypocalcemia after Billroth II Gastric Bypass Surgery.
    Schmucker AM; Green DE; Montemuro PM
    Case Rep Endocrinol; 2020; 2020():8833723. PubMed ID: 32774945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Prostate Cancer with Multiple Bone Metastasis with High FGF23 Value Indicated by Intractable Hypocalcemia and Hypophosphatemia].
    Nishida S; Shigesawa I; Nagai S; Itoh N; Masumori N
    Hinyokika Kiyo; 2021 Jan; 67(1):47-51. PubMed ID: 33535298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis.
    Bitar ZI; Hajjiah AM; Maadarani OS; Elzoueiry MM; Gohar MR; Abdelfatah M; Alabdali F
    Nutr Metab Insights; 2024; 17():11786388231223604. PubMed ID: 38205220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Recurrent Severe Hypocalcemia with Prolonged Hospitalization and Readmissions After Single Dose of Denosumab in Metastatic Prostate Cancer Patient.
    Kc O; Dahal PH; Koirala M; Kothagundla CS; Al Zaghal E; Fahed R
    J Community Hosp Intern Med Perspect; 2022; 12(2):60-64. PubMed ID: 35712685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
    Dave V; Chiang CY; Booth J; Mount PF
    Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
    Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
    Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment.
    Gouli S; Wang J; Patel A; Allerton J
    Cureus; 2021 Aug; 13(8):e17046. PubMed ID: 34522524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
    Yasuda Y; Iwama S; Arima H
    Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Denosumab and Parenteral Iron Therapy Precipitating Severe Hypocalcemia and Hypophosphatemia.
    Ye S; Grill V; Luo J; Nguyen HH
    JCEM Case Rep; 2024 Feb; 2(2):luae005. PubMed ID: 38304007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.